Supplemental information

Systemic tumor-draining dual-agonist immunostimulatory nanoparticles combine with PD1 blockade for curative neoadjuvant immunotherapy

Prabhani U. Atukorale^{1,2,3*}, Taylor J. Moon^{1†}, Alexandr R. Bokatch^{1†}, Christina F. Lusi³, Jackson T. Routhier¹, Victoria J. Deng¹, Efstathios Karathanasis^{1,2*}

¹ Dept. of Biomedical Engineering, Case Western Reserve University School of Medicine, Cleveland OH 44106

² Case Comprehensive Cancer Center, Cleveland OH 44106

³ Department of Biomedical Engineering, University of Massachusetts, Amherst, MA 01003

† These authors contributed equally.

*Corresponding authors E.K. (<u>stathis@case.edu</u>) and P.U.A (patukorale@umass.edu)

Supplemental Table 1. Dynamic light scattering (DLS) and zeta potential characterization measurements of dual-agonist, single-agonist, and empty NPs.

Sample	DLS hydrodynamic diameter/rel. variance (nm)	Zeta potential (mV)
cdGMP/MPLA-NP	49.4/0.029	+0.038
cdGMP-NP	46.4/0.023	-0.766
MPLA-NP	48.4/0.031	-0.016
Empty NP cntl	51.2/0.026	-0.019



Supplemental Figure 1. (A) DLS (upper panel) and zeta potential (lower panel) measurements for single-agonist MPLA-only and cdGMP-only NPs. **(B)** DLS measurements performed for dual-agonist immuno-NP stability in PBS, water, and DMEM medium supplemented with 10% serum carried out in independent triplicate.



Supplemental Figure 2. Measurement of fluorescence of independent NP formulations. Statistics by 2-way ANOVA with Tukey's post-test.



Supplemental Figure 3. Mouse weight change percentage following the start of treatment.



Supplemental Figure 4. Spleen mass on day 11 following the start of treatment on day 7. Statistics by 1-way ANOVA with Tukey's post-test.